Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Autoimmune Pharmaceutical Market in China 2021
15 March 2021
The autoimmune pharmaceutical market in China in terms of revenue is set to grow by US$ 12 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 26.6% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for autoimmune pharmaceutical. The China autoimmune pharmaceutical market is segmented on the basis of type. By type, it is categorized into psoriasis, rheumatoid arthritis, spondylitis ankylosans, and systemic lupus erythematosus (SLE).
The report has profiled some of the key players of the market such as AbbVie Inc., Bristol-Myers Squibb Company, Johnson & Johnson International Inc., Novartis International AG, Pfizer Inc., Roche Holding AG, Sanofi S.A..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the autoimmune pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Type: psoriasis, rheumatoid arthritis, spondylitis ankylosans, and systemic lupus erythematosus (SLE)
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China autoimmune pharmaceutical market
Pinpoint growth sectors and trends for investment
Understand what the future of the autoimmune pharmaceutical market in China looks like
Identify the competitive landscape and window of opportunity
Table of Contents
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Autoimmune Pharmaceutical Market by Type
4.2 Rheumatoid Arthritis
4.3 Spondylitis Ankylosans
4.4 Systemic Lupus Erythematosus (Sle)
5. Company Profiles
5.1 AbbVie Inc.
5.2 Bristol-Myers Squibb Company
5.3 Johnson & Johnson International, Inc.
5.4 Novartis International AG
5.5 Pfizer, Inc.
5.6 Roche Holding AG
5.7 Sanofi S.A.
6.1 About StrategyHelix